Brenner Erin K. 4
4 · Pear Therapeutics, Inc. · Filed Dec 9, 2022
Insider Transaction Report
Form 4
Brenner Erin K.
Chief Product Dev. Officer
Transactions
- Exercise/Conversion
Common Stock
2022-12-09$1.00/sh+15,000$15,000→ 30,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2022-12-09−15,000→ 90,234 totalExercise: $1.00Exp: 2028-09-20→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]100% of the shares subject to this option are fully vested and exercisable.
- [F2]Received in accordance with the terms of the Business Combination Agreement (the "Business Combination Agreement") dated as of June 21, 2021, by and among Thimble Point Acquisition Corp., Oz Merger Sub, Inc. and Pear Therapeutics (US), Inc. (f/k/a Pear Therapeutics, Inc.) ("Private Pear"), in exchange for an option to acquire 81,659 shares of common stock of Private Pear for $1.46 per share.